FindTrial
Sign In

Post-marketing surveillance of donepezil hydrochloride -Investigation of the clinical safety and effectiveness in patients with Alzheimer's Disease-

Post-marketing surveillance of donepezil hydrochloride -Investigation of the clinical safety and effectiveness in patients with Alzheimer's Disease-

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080221997
Enrollment
1000
Registered
2013-01-09
Start date
2013-01-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

investigational material(s) Generic name etc : Aricept INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for In

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed as Alzheimer's Disease by DSM-IV. Patients diagnosed as mild or moderate Alzheimer's Disease, applicable to FAST score 4 or 5.

Exclusion criteria

Exclusion criteria: Patients who used Aricept within 3 months prior to dosing. Patients registered this survey before. Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.

Design outcomes

Primary

MeasureTime frame
Test of cognitive function ADAS-Jcog—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026